The abstract is read at the publisher; the summary is JClub's.
GenSci143, a B7-H3 × PSMA-directed bispecific antibody-drug conjugate, produced profound tumor regression in prostate cancer xenograft models and showed superior antitumor activity versus competitor ADCs.
- Why it matters: ADCs face challenges from heterogeneous antigen expression, limited efficacy, and acquired resistance, limiting curative potential in metastatic castration-resistant prostate cancer.
- What they did: The study preclinically evaluated GenSci143, using gene profiling to support dual targeting, then tested binding, internalization, cytotoxicity, bystander killing, and compared performance against single-target clinical benchmark ADCs.
- The result: In multiple cancer cell line-derived and patient-derived xenograft models, GenSci143 demonstrated robust regression and superior activity, and in nonhuman primates it had excellent plasma stability with favorable pharmacokinetics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.